美国 · SEC FORM 4
Solid Biosciences Inc.
SLDB · Nasdaq · CIK 0001707502 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
2 同一窗口内观察到的 Form 4 交易行
0 sales · 2 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-03-11 · Kahn Clare · $9.9K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
SMITH IAN FDirector
○○
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-03-11 · Kahn Clare.
近期 Form 4 活动
0买入
29卖出
33其他 Form 4 交易行
34SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他2 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 12,726,346
- 上期报告
- 17,106,152
- 日均成交量
- 1,655,956
- 回补天数
- 7.7
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-03-11 | Kahn Clare | 买入 (P) | Common Stock | 1,860 | USD 5.34 | USD 9,932 | SEC 申报 ↗ |
| 2025-02-19 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive Xontogeny Venture Fund, LP | 买入 (P) | Common Stock | 5,000,000 | USD 4.03 | USD 20,150,000 | SEC 申报 ↗ |
| 2025-02-19 | BCIP Life Sciences Associates, LP; BCLS II Equity Opportunities GP, LLC; BCLS II Equity Opportunities, LP; BCLS II Investco (GP), LLC; BCLS II Investco, LP; BCLS SB Investco, LP; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Partners, LP | 买入 (P) | Common Stock | 1,000,000 | USD 4.03 | USD 4,030,000 | SEC 申报 ↗ |
| 2025-02-18 | Adage Capital Management, L.P.; Atchinson Robert; Gross Phillip | 买入 (P) | Common Stock, $0.001 par value per share | 252,545 | USD 7.56 | USD 1,909,240 | SEC 申报 ↗ |
| 2024-06-07 | Kahn Clare | 买入 (P) | Common Stock | 1,100 | USD 7.67 | USD 8,437 | SEC 申报 ↗ |
| 2024-01-11 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 904,160 | USD 5.53 | USD 5,000,005 | SEC 申报 ↗ |
| 2024-01-11 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive Xontogeny Venture Fund, LP | 买入 (P) | Common Stock | 3,410,713 | USD 5.53 | USD 18,861,243 | SEC 申报 ↗ |
| 2021-03-23 | EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 买入 (P) | Common Stock | 2,608,695 | USD 5.75 | USD 14,999,996 | SEC 申报 ↗ |
| 2021-03-19 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 2,206,685 | USD 5.75 | USD 12,688,439 | SEC 申报 ↗ |
Form 4 申报证据
62 transaction lines in the latest 365-day window; 207 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | SMITH IAN F | 期权行权／转换 (M) | Common Stock | 3,440 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-02 | SMITH IAN F | 期权行权／转换 (M) | Common Stock | 3,440 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-02 | SMITH IAN F | 期权行权／转换 (M) | Common Stock | 3,441 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | SMITH IAN F | 期权行权／转换 (M) | Common Stock | 3,440 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-02 | SMITH IAN F | 期权行权／转换 (M) | Common Stock | 3,440 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-02 | SMITH IAN F | 期权行权／转换 (M) | Common Stock | 3,441 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-18 | Tan Kevin | 卖出 (S) | Common Stock | 5,404 | USD 5.82 | USD 31,451 | SEC 申报 ↗ |
| 2026-02-18 | Howton David T | 卖出 (S) | Common Stock | 7,469 | USD 5.82 | USD 43,470 | SEC 申报 ↗ |
| 2026-02-18 | Herzich Paul | 卖出 (S) | Common Stock | 3,616 | USD 5.82 | USD 21,045 | SEC 申报 ↗ |
| 2026-02-18 | Hanrahan Jessie | 卖出 (S) | Common Stock | 4,134 | USD 5.82 | USD 24,060 | SEC 申报 ↗ |
| 2026-02-18 | Ganot Ilan | 卖出 (S) | Common Stock | 2,658 | USD 5.82 | USD 15,470 | SEC 申报 ↗ |
| 2026-02-18 | Cumbo Alexander | 卖出 (S) | Common Stock | 16,644 | USD 5.82 | USD 96,868 | SEC 申报 ↗ |
| 2026-02-18 | Brooks Gabriel | 卖出 (S) | Common Stock | — | USD — | USD — | SEC 申报 ↗ |
| 2026-02-13 | Tan Kevin | 期权行权／转换 (M) | Common Stock | 10,625 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-13 | Howton David T | 期权行权／转换 (M) | Common Stock | 14,687 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-13 | Herzich Paul | 期权行权／转换 (M) | Common Stock | 7,187 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-13 | Hanrahan Jessie | 期权行权／转换 (M) | Common Stock | 8,125 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-13 | Ganot Ilan | 期权行权／转换 (M) | Common Stock | 4,861 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-13 | Cumbo Alexander | 期权行权／转换 (M) | Common Stock | 30,031 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-13 | Brooks Gabriel | 期权行权／转换 (M) | Common Stock | 10,937 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-04 | Tan Kevin | 卖出 (S) | Common Stock | 14,783 | USD 6.44 | USD 95,203 | SEC 申报 ↗ |
| 2026-02-04 | Howton David T | 卖出 (S) | Common Stock | 18,894 | USD 6.44 | USD 121,677 | SEC 申报 ↗ |
| 2026-02-04 | Herzich Paul | 卖出 (S) | Common Stock | 10,905 | USD 6.44 | USD 70,228 | SEC 申报 ↗ |
| 2026-02-04 | Hanrahan Jessie | 卖出 (S) | Common Stock | 12,348 | USD 6.44 | USD 79,521 | SEC 申报 ↗ |
| 2026-02-04 | Ganot Ilan | 卖出 (S) | Common Stock | 7,205 | USD 6.44 | USD 46,400 | SEC 申报 ↗ |
| 2026-02-04 | Cumbo Alexander | 卖出 (S) | Common Stock | 48,913 | USD 6.44 | USD 315,000 | SEC 申报 ↗ |
| 2026-02-04 | Brooks Gabriel | 卖出 (S) | Common Stock | 12,616 | USD 6.44 | USD 81,247 | SEC 申报 ↗ |
| 2026-02-02 | Tan Kevin | 卖出 (S) | Common Stock | 26,837 | USD 6.44 | USD 172,830 | SEC 申报 ↗ |
| 2026-02-02 | Howton David T | 卖出 (S) | Common Stock | 37,771 | USD 6.44 | USD 243,245 | SEC 申报 ↗ |
| 2026-02-02 | Herzich Paul | 卖出 (S) | Common Stock | 26,250 | USD 6.44 | USD 169,050 | SEC 申报 ↗ |
| 2026-02-02 | Hanrahan Jessie | 卖出 (S) | Common Stock | 26,535 | USD 6.44 | USD 170,885 | SEC 申报 ↗ |
| 2026-02-02 | Cumbo Alexander | 卖出 (S) | Common Stock | 80,258 | USD 6.44 | USD 516,862 | SEC 申报 ↗ |
| 2026-02-02 | Brooks Gabriel | 卖出 (S) | Common Stock | 28,335 | USD 6.44 | USD 182,477 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SLDB |
| CIK | 0001707502 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 207 transaction lines from 2020-02-10 to 2026-10-02 9 P purchase lines · 76 S sale lines · 122 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.